Cost-Consequence Analysis of Sacubitril/Valsartan versus Enalapril in Chronic Heart Failure Patients with Reduced Ejection Fraction
Purpose: The rising prevalence of heart failure (HF) in midlife years in Indians is posing an economic challenge. Sacubitril/valsartan demonstrated a significant risk reduction of cardiovascular deaths by 20% and HF rehospitalizations by 21% versus enalapril but has a higher drug cost. High cost is...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca
2021-07-01
|
| Серія: | Applied Medical Informatics |
| Предмети: | |
| Онлайн доступ: | https://ami.info.umfcluj.ro/index.php/AMI/article/view/811 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|